- Home
- DAVA vs IVVD Comparison
DAVA vs IVVD Comparison
Compare DAVA & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | IVVD |
|---|---|---|
| Founded | 2000 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.7M | 437.1M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DAVA | IVVD |
|---|---|---|
| Price | $4.65 | $1.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $14.57 | $8.75 |
| AVG Volume (30 Days) | 524.0K | ★ 2.2M |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,384,000.00 |
| Revenue This Year | N/A | $107.86 |
| Revenue Next Year | $4.26 | $146.53 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.38 | $0.46 |
| 52 Week High | $24.40 | $3.07 |
Technical Indicators
Market Signals| Indicator | DAVA | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 33.20 | 43.32 |
| Support Level | N/A | $1.41 |
| Resistance Level | $7.04 | $2.01 |
| Average True Range (ATR) | 0.37 | 0.11 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 19.34 | 67.74 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.